|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.40 EUR | -0.38% |
|
-0.84% | -15.37% |
| 12-11 | Merck KGaA's SpringWorks Gets UK Clearance for Plexiform Neurofibromas Therapy | MT |
| 12-11 | UK's MHRA approves mirdametinib to treat plexiform neurofibromas | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MERCK KGAA | Specialty & Advanced Pharmaceuticals | -0.38% | -0.84% | -15.37% | -17.89% | -11.14% | 60.86B |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- MRK Stock
- Charts Merck KGaA
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition